News stories about Arrowhead Pharmaceuticals (NASDAQ:ARWR) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.8043958257397 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

ARWR opened at $6.66 on Friday. Arrowhead Pharmaceuticals has a 1 year low of $1.42 and a 1 year high of $8.09. The stock has a market capitalization of $573.66, a price-to-earnings ratio of -14.17 and a beta of 2.36. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.87 and a current ratio of 3.87.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Friday, February 9th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.04). Arrowhead Pharmaceuticals had a negative net margin of 116.17% and a negative return on equity of 42.52%. The firm had revenue of $3.51 million during the quarter, compared to analyst estimates of $8.71 million. analysts expect that Arrowhead Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Several analysts recently commented on ARWR shares. BidaskClub raised Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 1st. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, February 19th. ValuEngine raised Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Cantor Fitzgerald set a $5.00 price objective on Arrowhead Pharmaceuticals and gave the stock a “neutral” rating in a research note on Monday, February 12th. Finally, Jefferies Group started coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, March 27th. They set a “buy” rating and a $10.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $6.30.

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, March 27th. The stock was sold at an average price of $8.00, for a total value of $160,000.00. Following the sale, the chief financial officer now owns 330,815 shares of the company’s stock, valued at approximately $2,646,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Christopher Richard Anzalone sold 100,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $7.43, for a total value of $743,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,194,789 shares in the company, valued at approximately $16,307,282.27. The disclosure for this sale can be found here. Insiders sold a total of 465,000 shares of company stock worth $3,432,350 in the last three months. Company insiders own 4.60% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Insider Buying and Selling by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.